Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited American Depositary Shares
(NY:
TEVA
)
34.22
-0.11 (-0.32%)
Official Closing Price
Updated: 7:00 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited American Depositary Shares
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
32
33
Next >
Earnings Scheduled For November 8, 2023
↗
November 08, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
Via
Benzinga
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
November 07, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
November 02, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
November 01, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alkermes Q3 Earnings Top Consensus, On Track To Separate Oncology Business, Reaffirms FY23 Outlook
↗
October 25, 2023
Alkermes PLC (NASDAQ: ALKS) reported Q3 FY23 adjusted EPS of $0.64 compared to $0.02 a year ago, beating the
Via
Benzinga
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
October 25, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
↗
October 23, 2023
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.
Via
Investor's Business Daily
Israeli-Hamas War: U.S. Exchange-Listed Israeli Stocks Continue To Decline
↗
October 22, 2023
The 111 Israeli companies with stocks trading on US exchanges have combined market caps over $150B. Or at least they did midweek: since the Hamas-Israeli War began October 7th, pretty much everything...
Via
Talk Markets
Investor Exit Israel ETFs Following Attacks, But Remain Confident In Large-Caps
↗
October 19, 2023
Israel-focused ETFs have plunged since the last trading day before Hamas launched surprise attacks on Israel, while some Israeli companies listed in the U.S. have so far escaped repercussions to their...
Via
Benzinga
Topics
ETFs
Thoughts For Thursday: War Worries Rattle The Market
↗
October 19, 2023
Via
Talk Markets
Hamas-Israeli War: US Exchange Listed Israeli Stocks Hit Hard
↗
October 18, 2023
111 Israeli companies trade on U.S. stock exchanges of which only 15 have market capitalization of $2B or more.
Via
Talk Markets
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
October 17, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Israel Could Form Emergency Government: Defense Stocks, Israel ETFs In Focus During Conflict
↗
October 10, 2023
As Israel ramps up its armed forces and a regional war with Hamas enters its fourth day, the country is considering forming an emergency government.
Via
Benzinga
Topics
ETFs
Israeli Stocks Fall as Investors Fear Middle East Conflict
↗
October 09, 2023
The recent attacks on Israel will have a lasting economic impact. Here's what investors should know about Israeli stocks.
Via
InvestorPlace
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
↗
October 09, 2023
Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil.
Via
Benzinga
Topics
ETFs
Why Teva Pharmaceutical (TEVA) Stock Is Falling
↗
October 09, 2023
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) shares are trading lower by 2.7% to $9.17 Monday morning amid conflict in the company's home country, Israel.
Via
Benzinga
Middle East War Hammers Israel-Based Stocks But Lifts Defense, Oil Names
↗
October 09, 2023
Israel stocks, regardless of industry, sank Monday following the terrorist attack on Israel.
Via
Investor's Business Daily
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
October 06, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Palantir And PwC Team Up To Accelerate Data-Driven Operations, OpenAI Rival Secures Billions In Big Tech Backing, Six US States Brace For Healthcare Strike: Today's Top Stories
↗
October 04, 2023
Benzinga
Via
Benzinga
Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.
↗
October 04, 2023
The deal leans into the emerging TL1A drug class, potentially rivaling Roivant and Merck.
Via
Investor's Business Daily
Sanofi, Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People
↗
October 04, 2023
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and
Via
Benzinga
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
October 04, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
October 02, 2023
Via
Benzinga
Teva Announces Changes to Executive Management Team
September 28, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
↗
September 27, 2023
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO
Via
Benzinga
Topics
Artificial Intelligence
Migraine Medication Battle: Eli Lilly Prevails in Patent Infringement Case Against Teva
↗
September 27, 2023
A federal judge in Massachusetts has overturned a $176.5 million jury verdict against Eli Lilly And Co (NYSE: LLY). T
Via
Benzinga
Topics
Intellectual Property
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
↗
September 26, 2023
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to...
Via
Benzinga
3 No-Brainer Stocks to Buy With $20 Right Now
↗
September 13, 2023
You don't need a boatload of cash to begin growing your wealth on Wall Street.
Via
The Motley Fool
Why Can't You Find Adderall? Inside the Ongoing Shortage of ADHD Medication In US
↗
September 12, 2023
Last year, Teva Pharmaceutical Industries Ltd (NYSE: TEVA), the primary producer of Adderall, faced shortages
Via
Benzinga
TEVA - A Pharma Stock To Watch
↗
September 11, 2023
TEVA is one of the few instruments that has handily cleared its July 6-month calendar range high. The 50 daily moving average is about to cross or golden cross the 200-DMA and enter a bullish phase.
Via
Talk Markets
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
32
33
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.